COPY OF PAPERS ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kristof CHWALISZ et al.

Serial No.: 10/043,232

Group Art Unit: 1617

Filed: January 14, 2002

Examiner: TBA

IMPLANTATION RATES AFTER IN VITRO FERTILIZATION, AND TREATMENT OF INFERTILITY AND EARLY PREGNANCY LOSS WITH A NITRIC OXIDE DONOR OR SUBSTRATE ALONE OR IN COMBINATION WITH PROGESTERONE, AND A METHOD FOR CONTRACEPTION WITH NITRIC OXIDE INHIBITORS IN COMBINATION WITH ANTIPROGESTINS OR OTHER AGENTS

I

INFO	<u>ORMA'</u>	TION DISCLOSURE STATEM	MENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98		
		mmissioner for Patents D. C. 20231	I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope		
Sir:			addressed To: Commissioner of Patents and Trademarks, Washington, D.C. 20231 On: Name:		
	CITE	D MATERIALS	Signature: Alianal Bring Date: Alianal Bring		
	Applicant(s) hereby disclose the information listed in the attached form PTO-1449.				
		Copies of materials listed but no No. <u>09/162,446</u> ; see 37 C.F.R.	ot attached were cited in parent application Serial § 1.98(d).		
		Report dated; receipt or	ot attached were cited in an International Search f the International Search Report and copies of e PCT International Division of the U.S. PTO in ed		
	ADDITIONAL INFORMATION				
	NON	Е			
	LANC	<u>GUAGE</u>			
		All listed materials are in the E	nglish language; see 37 C.F.R. § 1.98.		
		Non-English language referenc	es:		
		☐ The reference(s): commercial data bases to corre	in the English-language is (are) indicated by spond to the reference(s): , respectively.		
		☐ (An) English-language provided.	translation(s) of the references: is (are)		
		☐ A commercial English-provided.	language abstract of reference(s) is (are)		

	patent of	An English-language search report or an equivalent paper from a foreign office translated into English in pertinent part in connection with a part foreign application, is provided indicating the relevance of the cited e(s).		
FEES				
\boxtimes	No fee i	s required for this Information Disclosure Statement because:		
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;			
		This Information Disclosure Statement is being filed before the mailing of ction on the merits;		
·	the merinotice o	This Information Disclosure Statement is being filed after a first action on its but before the mailing date of any of a final action under § 1.113, a f allowance under § 1.311, or an action that closes prosecution in the ion, and is accompanied by a certification below.		
		This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).		
	A fee is required for this Information Disclosure Statement:			
	the meri notice o	This Information Disclosure Statement is being filed after a first action on ts but before the mailing date of any of a final action under § 1.113, a f allowance under § 1.311 or an action that closes prosecution, and is anied by the fee set forth in §1.17(p).		
	of a final prosecut	This Information Disclosure Statement is being filed after the mailing date I rejection or a notice of allowance under § 1.311 or an action that closes ion, but before the payment of the issue fee, and is accompanied by the orth in § 1.17(p) and a certification below.		
CERTI	FICATIO	<u>ON</u>		
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.			
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.			

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\sum_\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nancy J. Axelrod, Reg. No. 44,014 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO& BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

FILED: <u>April 15, 2002</u>